Australia Markets closed

Bioxyne Limited (BXN.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.02300.0000 (0.00%)
At close: 10:54AM AEDT

Bioxyne Limited

50 Clarence Street
Suite 506 Level 5
Sydney, NSW 2000
61 2 9078 8180

Sector(s)Consumer Defensive
IndustryPackaged Foods
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Nam Hoat Chua B.A., BAMD, Joint-CEO & Director190.32kN/AN/A
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), C.A., CA, MAICDCFO, Company Sec. & Exec. Director80kN/A1955
Mr. Sam WatsonJoint Chief Exec. OfficerN/AN/AN/A
Ms. Rachel QianFinancial Controller & Assistant Company Sec.N/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Bioxyne Limited, a life sciences and health products company, researches, develops, markets, and distributes dietary supplement and beauty products. It perates in two segments, Wholesale Sales and Direct Sales. The company engages in developing various functional foods and beauty products. Its products portfolio includes Progastrim for Gut and Immune Health; Progastrim plus Vitamin C for cold symptoms; and proTract for atopic dermatitis (eczema) for infants. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.

Corporate governance

Bioxyne Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.